Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer

SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep' or 'the Company'), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces topline results from the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alfa (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA (pembrolizumab) as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma patients (1L HNSCC).

The trial enrolled 171 patients with any PD-L1 expression (Combined Positive Score [CPS] 1) and negative PD-L1 expression (CPS

(C) 2024 Electronic News Publishing, source ENP Newswire